Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic kidney-harm claims (crystallization in urinary tract, crystal obstruction, creatinine/urine output pattern, hydration/urine concentration as primary driver, recovery expectations) are not supported by the provided FDA label excerpts. The only clearly label-supported elements in the prompt relate to indications, general renal failure warning, contraindication, and a probenecid interaction. Therefore overall alignment is partial.
Category Scores
Accurate Statements
Clinicians monitor kidney function during acyclovir treatment when risk is present.
Not supported by the provided label excerpts (no monitoring language supplied).
Acyclovir is contraindicated for patients with hypersensitivity to acyclovir or valacyclovir.
SECTION 4 — CONTRAINDICATIONS
Unsupported Statements
Prolonged exposure to acyclovir can harm kidney function mainly by physically injuring kidney tissue and by worsening dehydration-related kidney stress.
No provided excerpt describes mechanisms as physical kidney tissue injury or dehydration-related stress as the main pathway.
Acyclovir can form crystals in the urinary tract.
No provided excerpt supports urinary tract crystal formation.
Acyclovir crystal formation can block urine flow and lead to kidney injury.
No provided excerpt supports urinary blockage from acyclovir crystals.
Acyclovir crystal formation can produce acute kidney injury patterns including rises in creatinine and decreased urine output.
No provided excerpt provides this specific clinical pattern or ties it to crystal obstruction.
Acyclovir kidney injury is often most likely with higher doses and inadequate hydration.
Provided excerpts include a renal failure warning but do not specify dose-hydration relationship or hydration as determinant.
Acyclovir kidney injury can be more severe when kidney function is already reduced.
General renal impairment dosing adjustment is referenced, but the provided excerpts do not make this severity statement.
Acyclovir has been associated with tubular injury mechanisms that can impair kidney function.
No provided excerpt describes tubular injury mechanisms.
Acyclovir can damage kidney tubules enough to trigger acute kidney injury even without complete urinary blockage.
Not supported by provided excerpts.
The likelihood and severity of kidney harm from acyclovir increase when exposure is combined with factors that reduce kidney clearance or further stress the kidneys.
No provided excerpt quantifies or lists combined-risk interactions for severity.
Dehydration or low effective fluid intake concentrates urine and promotes crystallization, increasing risk.
No provided excerpt supports urine concentration/crystallization mechanism or dehydration as promoting crystallization.
Pre-existing kidney impairment increases acyclovir exposure in the body and in the kidney environment.
The excerpts indicate pharmacokinetics and dose modification for renal impairment, but the specific claim about increased exposure 'in the kidney environment' and the exposure comparison is not provided verbatim or clearly supported.
Using other nephrotoxic agents or medications that stress renal function at the same time increases the risk of kidney harm when multiple kidney risks overlap.
Provided drug interaction excerpt only mentions probenecid with IV acyclovir; no nephrotoxic-agent overlap guidance is supplied.
Kidney injury from acyclovir can cause reduced urine output or difficulty urinating.
Not supported by provided adverse reaction excerpts.
Kidney injury from acyclovir can cause rising serum creatinine and other signs of declining kidney function.
No provided excerpt includes these lab/clinical signs.
Crystal-related and injury-related kidney effects from acyclovir are most likely when urine is concentrated and acyclovir levels are high.
No provided excerpt supports crystal-related effects or urine concentration/high levels linkage.
High-dose regimens or prolonged dosing can lead to high acyclovir levels.
No provided excerpt states this relationship.
Reduced baseline kidney function can lead to higher effective drug exposure.
No provided excerpt states increased exposure resulting from reduced baseline kidney function in the specific wording claimed.
In many cases, kidney injury improves after stopping acyclovir and correcting contributing factors like dehydration.
No provided excerpt includes recovery frequency or dependency on stopping/correcting dehydration.
Recovery from acyclovir-related kidney injury depends on how severe the injury was and how quickly treatment is adjusted.
No provided excerpt states recovery dependence on severity/timing.
If kidney injury progresses, it can require more intensive management.
No provided excerpt includes management intensity guidance.
Clinicians reduce the risk of acyclovir-associated kidney injury by ensuring adequate hydration to reduce urine concentration.
No provided excerpt provides hydration/urine concentration prevention language.
Clinicians reduce the risk of acyclovir-associated kidney injury by using dose adjustments for impaired kidney function so drug levels do not build up.
While renal impairment dose modification exists (SECTION 2), the specific rationale 'so drug levels do not build up' is not provided in the supplied excerpt.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Renal failure is explicitly warned/observed (including some cases resulting in death) but the AI response does not clearly align to the label wording beyond general kidney injury mechanism statements.
Importance:
Moderate
No mention of probenecid interaction with (IV) acyclovir, which is the only specific drug-interaction example provided in the excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The response contains multiple mechanistic and clinical-pattern claims (crystal formation/urinary obstruction, creatinine/oliguria pattern, hydration/urine concentration as primary risk modulator) that are not supported by the provided label excerpts. While the label does warn that renal failure has been observed, unsupported mechanistic specificity could mislead interpretation of risk and mitigation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many kidney-related mechanism and monitoring/recovery/hydration specifics are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit kidney-related statements to what is explicitly supported in the provided excerpts (e.g., renal failure observed as a warning/adverse event and that renal impairment requires dose modification per Table 3), and avoid asserting crystal formation, urinary obstruction, specific creatinine/urine-output patterns, and hydration/urine-concentration causality unless verbatim label support is provided.